Drug data last refreshed 18h ago · AI intelligence enriched 1mo ago
Niclosamide is an oral anthelmintic (antiparasitic) agent administered as a chewable tablet for the treatment of parasitic infections. The drug acts by inhibiting oxidative phosphorylation in parasite mitochondria, leading to parasite death. It is indicated for infections caused by cestodes (tapeworms) and other susceptible parasites.
Pre-launch status indicates commercial infrastructure is being built; this represents early-stage hiring for brand launch roles across marketing, medical affairs, and field teams.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Niclosamide in COVID-19
Niclosamide In Moderate COVID-19
Safety and Efficacy of Intranasal Administration of Niclosamide (UNI91103) in Adults With Asymptomatic or Mild COVID-19
Safety and Efficacy of Niclosamide in Patients With COVID-19 With Gastrointestinal Infection
Safety and Preliminary Efficacy of the Combination of Niclosamide and Camostat
Worked on NICLOCIDE at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on Niclosamide pre-launch positions professionals at the ground floor of a specialized parasitic disease product entering the U.S. market. This represents a focused commercial opportunity in a niche therapeutic area with relatively low competition and defined market dynamics.